Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
None of the CD34(+)Lin(-) hematopoietic stem cell progenitors or the CD34(+)CD19(+) (pro-B) or the CD19(+)CD10(+) (pre-B/immature B cells) B-cell progenitors expressed CCR6.
|
11001880 |
2000 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this prospective study, samples from 478 patients with CD10(+) B-cell precursor ALL (c-ALL and pre-B ALL) underwent BCR-ABL reverse transcription-polymerase chain reaction (RT-PCR) analysis with double testing of positive samples.
|
11861265 |
2002 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of these, 42 children with a common/pre-B phenotype (CD19/CD10-positive) were studied specifically to assess CD10 antigen density.
|
1465029 |
1992 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of BCR/ABL-positive patients, 83% had early pre-B ALL, one patient had pre-T ALL, while half of the BCR/ABL-negative patients had early pre-B ALL, 18% had CD10-negative pro-B ALL and 21% were pre-T.
|
9369422 |
1997 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thirty-seven of them were common-ALL positive for CD10 "common-ALL antigen (CALLA)" (NL-1), CD19(B4) and HLA-DR. One was pre-B ALL negative for CALLA and another null-ALL which expressed HLA-DR alone.
|
2959808 |
1987 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
All t-ALL cases had a pro-B (CD10-negative) immunophenotype with significantly higher expression of CD15 and CD65, compared to the de novo CD10-positive ALL cases.
|
12764373 |
2003 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
All reported patients had CD10+ pre-B-cell All, and achieved remission, as was the case for our four pediatric dic(9;20) patients.
|
8976366 |
1996 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To elucidate the biologic and clinical heterogeneity of adult pro-B acute lymphoblastic leukemia (ALL) (ie, terminal deoxynucletidyl-transferase-positive[TdT+], CD19+, CD10-, surface immunoglobulin-negative [SIg-]), we evaluated 66 patients enrolled in the Italian multicentric Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) 0496 study between October 1996 and December 1999.
|
12791662 |
2003 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The predominant expression of Ik-6, which is the result of post-transcription dysregulation, is characteristic of adult pre-B ALL, especially CD10(+) pre-B ALL.
|
12094252 |
2002 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chromosomal translocation was identified in 24 (36.4%) of the ALL patients, 17 of whom had recurrent translocations including 10 with CD10+ B-precursor ALL [4 with t(9;22), 5 with t(1;19), and 1 infant with t(8;14)(q24;q11)], one neonate with CD10- early pre-B ALL with t(4;11), three B-cell cases with t(8;14), and three T-cell cases [2 with t(11;19)(q23;p13), and 1 (11;14)(p13;q11)].One B-precursor patient had dic (9;12).
|
10870310 |
2000 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This in vivo cell line, designated PALL-I, retained the Ph1 chromosome, t(9;22) (q34;q11), and pre-B-cell phenotype (SmIg-, CpIg-, CD10+, CD19+, OKIaI+, and CD38+), like the original leukemia cells.
|
2732004 |
1989 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
All cases had a pre-B phenotype; 12 (57%) of them were pre-pre-B ALL (CD10-, CD19+).
|
1316141 |
1992 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The TPA-induced down-regulation of CALLA on REH cells was demonstrated with the aid of the following CD10 monoclonal antibodies: J-5, VIL-A1 and DGH-10-1-A9.
|
2148811 |
1990 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that several of the clinical and laboratory prognostic factors, which are used reliably for B-precursor ALL, are much less predictive in T-ALL (ie age, WBC, consensus risk group, hyperdiploidy, presence of trans- locations and CALLA expression).
|
10557041 |
1999 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The three cases with germ line IgJH and C mu loci were revealed to belong to stage I (HLA DR+), stage II (HLADR+, CD19+), and stage III (HLADR+, CD19+, CD10+) B precursor ALLs, respectively.
|
2304358 |
1990 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast to childhood acute lymphoblastic leukemia (ALL), the cell-biological features, clinical characteristics, and treatment outcome of CD10(-) pro-B ALL have not yet been determined in larger series of adult patients.
|
9731046 |
1998 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 63 cases positive for the TEL/AML1 chimeric products ranged in age between 1 and 12 years, and all but one showed CD10 and pre-B immunophenotype.
|
9226156 |
1997 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, only two patients from a group of 67 common (CD19/CD10+, cylgM/sIgM-) and pre-B ALLs (CD19/cylgM+, CD10 +/-, sIgM-) showed ALL1-AF4 mRNA.
|
7949140 |
1994 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data identify CD10- cytoplasmic immunoglobulin-positive pre-B ALL as a rare (2.2%) but distinct immuno-subtype of adult ALL that is characterized by a high MLL rearrangement rate and a worse outcome.
|
16123216 |
2005 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The most predominant CD10-positive pre-B-cell type, corresponding to a precursor B-cell neoplasm, frequently involves the head and neck.
|
8534767 |
1995 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Persistence of TEL-AML1 fusion gene as minimal residual disease has no additive prognostic value in CD 10 positive B-acute lymphoblastic leukemia: a FISH study.
|
18928518 |
2008 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition to features characteristic of myeloma cells, we found evidence of the frequent expression by myeloma tumor cells of the pre-B-cell antigen CALLA (common acute lymphocytic leukemia antigen) (in specimens from 58 percent of patients) and of megakaryocytic (88 percent), myelomonocytic (65 percent), and erythroid (39 percent) surface markers.
|
2137556 |
1990 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Eleven of the 20 patients (55%) were positive for the CD10 antigen and therefore classified as common ALL.
|
1554798 |
1992 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Normal karyotype CALLA-positive adult pre-B ALL: dismal outcome with chemotherapy for patients with loss/gain of ABL1 and/or BCR FISH signals.
|
23098889 |
2013 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A CD10 (common ALL antigen)-negative, CD19-positive pre-pre-B ALL phenotype was observed in 24 infants.
|
2725059 |
1989 |